SCM Lifescience CEO On Developing High Purity, Disease-Specific Stem Cell Therapies
Executive Summary
Emerging Company Profile: Capitalizing on its proprietary platform technologies designed to develop high efficacy, disease-specific and low cost stem cell products, South Korea's SCM Lifescience aims to prove in clinical trials how its product candidates differ from existing stem cell therapies.
You may also be interested in...
Korean Firms Join Hands To Pick Up Troubled US Cancer Vaccine Firm Argos
Argos Therapeutics lands in the hands of Genexine and SCM Lifescience after the US immunotherapy firm was put up for sale by the Delaware bankruptcy court. The Korean biotechs plan to use the company’s cGMP facilities and experience in large US Phase III trials to accelerate their global market entry.
Samsung Looks Beyond Biosimilars Via Takeda Tie-Up
Samsung Bioepis is shifting gears moving into the development of novel biologics via a strategic collaboration with Takeda. The partners will initially focus on acute pancreatitis and jointly develop Takeda's preclinical candidate in the segment.
The Hunt For Big Fish: How KDDF Is Helping Create Korean Deals
Korea Drug Development Fund CEO H. Samuel Muk talks to Scrip how the government agency has evolved to support the Korean biopharma industry’s R&D and business development activities, as well as what key new projects are underway.